연구성과 상세
연구성과 상세
SiMPl-GS: Advancing Cell Line Development via Synthetic Selection Marker for Next-Generation Biopharmaceutical Production
-
- 작성일
-
- 조회수
- 32
구분 | 논문 | 연구분야명 | 동물 | ||||||
---|---|---|---|---|---|---|---|---|---|
연구책임자명(주관기관) | 이재성 | 소속기관명(주관기관) | 아주대학교 | ||||||
연구책임자명 (공동/위탁기관) |
이균민 | 소속기관명 (공동/위탁기관) |
한국과학기술원 | ||||||
학술지명 | Advanced science | 게재년월 | 2024-08 | ||||||
ISSN | DOI | https://doi.org/10.1002/advs.202405593 | |||||||
게재권 | 11 | 게재호 | 0 | ||||||
링크 | https://pubmed.ncbi.nlm.nih.gov/39105414/ | ||||||||
초록 | Rapid and efficient cell line development (CLD) process is essential to expedite therapeutic protein development. However, the performance of widely used glutamine-based selection systems is limited by low selection efficiency, stringency, and the inability to select multiple genes. Therefore, an AND-gate synthetic selection system is rationally designed using split intein-mediated protein ligation of glutamine synthetase (GS) (SiMPl-GS). Split sites of the GS are selected using a computational approach and validated with GS-knockout Chinese hamster ovary cells for their potential to enable cell survival in a glutamine-free medium. In CLD, SiMPl-GS outperforms the wild-type GS by selectively enriching high producers. Unlike wild-type GS, SiMPl-GS results in cell pools in which most cells produce high levels of therapeutic proteins. Harnessing orthogonal split intein pairs further enables the selection of four plasmids with a single selection, streamlining multispecific antibody-producing CLD. Taken together, SiMPl-GS is a simple yet effective means to expedite CLD for therapeutic protein production. |